AGRICULTURAL AND FOOD CHEMISTRY

Novel Ferulic Amide Ac6c Derivatives: Design, Synthesis, and Their Antipest Activity

Renfeng Zhang,[†] Shengxin Guo,[†] Peng Deng, Ya Wang, Ali Dai, and Jian Wu*

Cite This: http	s://doi.org/10.1021/acs.jafc.1c03	392	Read Online	I	
ACCESS	III Metrics & More		E Article Recommendations		s Supporting Information

ABSTRACT: Thirty-eight novel ferulic amide 1-aminocyclohexane carboxylic acid (Ac6c) derivatives **D1–D19** and **E1–E19** were designed and synthesized, and their antibacterial, antifungal, and insecticidal activities were tested. Most of the synthesized compounds displayed excellent activity against*Xanthomonas oryzae* pv. *oryzae* (*Xoo*), with EC₅₀ values ranging from 11.6 to 83.1 μ g/mL better than that of commercial bismerthiazol (BMT, EC₅₀ = 84.3 μ g/mL), as well as much better performance compared to that of thiediazole copper (TDC, EC₅₀ = 137.8 μ g/mL). **D6** (EC₅₀ = 17.3 μ g/mL), **D19** (EC₅₀ = 29.4 μ g/mL), **E3** (EC₅₀ = 29.7 μ g/mL), **E9** (EC₅₀ = 27.0 μ g/mL), **E10** (EC₅₀ = 18.6 μ g/mL), and **E18** (EC₅₀ = 20.8 μ g/mL) showed much higher activity on *Xanthomonas oryzae* pv. *oryzicola* compared with BMT (EC₅₀ = 80.1 μ g/mL) and TDC (EC₅₀ = 124.7 μ g/mL). In relation to controlling the fungus, *Rhizoctonia solani*, **E1**, **E10**, and **E13** had much lower EC₅₀ values of 0.005, 0.140, and 0.159 μ g/mL compared to hymexazol at 74.8 μ g/mL. Further *in vivo* experiments demonstrated that **E6** and **E12** controlled rice bacterial leaf blight disease better than BMT and TDC did. Scanning electron microscopy (SEM) studies revealed that **E12** induced the *Xoo* cell membrane collapse. Moreover, **D13** (73.7%), **E5** (80.6%), and **E10** (73.4%) also showed moderate activity against *Plutella xylostella*. These results indicated that the synthesized ferulic amide Ac6c derivatives showed promise as candidates for treating crop diseases. **KEYWORDS:** *ferulic amide, Ac6c derivatives, synthesis, antibacterial activity, antifungal activity, insecticidal activity*

INTRODUCTION

Crop pests and pathogens often result in quality and yield losses in agricultural production.¹⁻³ About 16–20% of the major food crop production is lost worldwide each year due to preharvest diseases.⁴ Xanthomonas oryzae pv. oryzae (Xoo) and X. oryzae pv. oryzicola (Xoc) are good examples, as they can cause devastating leaf blight and leaf stripe in rice crops and often lead to serious disease outbreaks, which reduce crop yield by 20%, rising to 50% under severe infection.⁵⁻⁸ In addition, as one of the most aggressive pathogens, Xanthomonas axonopodis pv citri (Xac) in citrus can cause serious canker and cut down citrus production worldwide; also, as it is difficult to control once plants are infected, it has a serious impact on the entire citrus industry.^{9–11} Currently, the use of chemical pesticides is still the main measurement taken to control crop diseases and pests. However, there is a severe shortage of available control agents and a limited number of actions to take against these diseases. This is especially true given the continuous increase in resistance or cross-resistance by the pests and pathogens to the existing pesticides;^{12,13} therefore, the prevention and control of crop pests are becoming more and more difficult. Hence, exploration of new active molecules with novel modes of action that exhibit high activity yet possess low-risk profiles for plant pests and pathogens is urgently needed.

Natural products (NPs) play a significant role in exploring novel pesticides. So far, more than 50% of the available commercial pesticides have been derived from NPs, these include conventional neonicotinoids, strobilurins, pyrethroids, ethylicin, fenpiclonil, and fludioxonil, all of which mimic NPs.¹ Nowadays, NP-based products are still hot topics for researching and developing novel agrochemicals due to their unique properties including biocompatibility with the environment and their novel modes of action.^{14–16} As an important natural product, the ferulic acid skeleton is the most widely used today as it is the lead compound in NP-based drug design.¹ Many molecules derived from ferulic acid have shown various physiological functions such as antioxidant,¹⁷ antibacterial,¹⁸ anticancer,¹⁹ anticoagulant,²⁰ and anti-inflammatory actions.²¹ In particular, ferulic acid based compounds have also been developed for inhibiting plant diseases in recent years. Some novel ferulic acid skeleton-based compounds, such as amide derivatives,²² chalcone derivatives,²³ α -amino phosphonates derivatives,²⁴ acylhydrazone derivatives,²⁵ and others, have reportedly shown promising activity in relation to plant disease control. In particular, combining an amino group with ferulic acid could lead to ferulic amides, which can potentially be used as fungicides in agriculture.^{24–28}

1-Aminocyclohexane carboxylic acid (Ac6c) is also an important non-proteinogenic quaternary α -amino acid, which plays an important role in synthetic antimicrobial peptide and drug discovery.²⁹ The compounds or peptide analogues containing Ac6c have shown excellent bioactivities including anticonvulsant,³⁰ antiproliferative,³¹ antitumor,³² antibacteri-

Received:	June 29, 2021
Revised:	August 3, 2021
Accepted:	August 11, 2021



pubs.acs.org/JAFC

Figure 1. Design strategy for the target molecules.





al,³³ insecticidal,³⁴ herbicidal,³⁵ antifungal,³⁶ and plant growth regulator activities toward improving drought resistance in plants.^{27,28} Some Ac6c derivatives also display excellent activity levels against *Phytophthora infestans* in tomato plants.³⁷ So far, about ~150 Ac6c pharmacophore-containing compounds have been discovered.³⁸ Moreover, the Ac6c structure displays two superiorities: (1) The cyclic ring and quaternary α -carbon atom in Ac6c could restrict its ability to become an intrinsically stable conformation. This feature often results in a more efficient and selective ligand than a nonrestricted one when they act upon the target.^{39,40} (2) Ac6c possesses a saturated cyclohexane core, ensuring that Ac6c derivatives are more lipophilic.⁴¹ These factors have ensured that interest in Ac6c derivatives has grown.

The method of "substructure combination" is often used in pesticide design.⁴² The rationale of this method is integrated with different substructures in some active compounds *via* a functional linker (such as amide, ether, etc.);^{23,43} based on this method, a potentially active compound might be obtained.^{23,24,42,43} Hence, encouraged by the qualities described above, we sought to combine the ferulic acid core with Ac6c *via* a functional amide, then achieve structural diversity through the reaction site at the hydroxyl on ferulic acid to produce novel ferulic amide Ac6c derivatives (Figure 1). Antibacterial activities of these derivatives were then tested on *Xoo*, *Xoc*, and *Xac*, and antifungal activities were evaluated against *Cytospora mandshur*-

ica, Colletotrichum gloeosporioides, Gibberella zeae, Sclerotinia sclerotiorum, Fusarium oxysporum, and Rhizoctonia solani. Insecticidal activity against diamondback moth (*Plutella.* xylostella) was also investigated. Successful results showed that most of the designed compounds showed outstanding antibacterial activity. *In vivo* experiments and the morphological influence on Xoo were also considered.

MATERIALS AND METHODS

Instruments and Chemicals. ¹H, ¹³C, and ¹⁹F NMR spectra were detected on a JEOL ECX 500 NMR (JEOL Ltd., Tokyo, Japan) or an AVANCE III HD 400M NMR (Bruker Corporation, Fallanden, Switzerland) spectrometer using dimethyl sulfoxide (DMSO) as the solvent. The melting points of the ferulic amide Ac6c derivatives **D1–D19** and **E1–E19** were measured by a binocular microscope melting point apparatus (XT-4, Beijing Tech Instrument Co., Beijing, China). High-resolution mass spectrometry (HR-MS) was given by an Orbitrap liquid chromatography–mass spectrometry (LC-MS) (Q-Exative, Thermo Scientific). Scanning electron microscopy (SEM) images were obtained and visualized using Nova NanoSEM 450 (Thermo Fisher Scientific, Massachusetts). Ferulic acid methyl ester was bought from TCI (Tokyo, Japan) and the substituted halogenated hydrocarbons and 1-aminocyclohexane carboxylic acid were supplied by Accela (Shanghai, China). All of the reactions were monitored by TLC.

General Procedure for Preparing D1–D19 and E1–E19. Scheme 1 depicts the synthetic route for the title compounds D1–D19 and E1–E19. They were provided *via* several steps that started from

Table 1. In Vitro Antibacterial Activity^a of the Target Compounds against Xoo, Xac, and Xoc

	Xoo		Xoc		Xac	
compd.	inhibition	n rate (%)	inhibition	n rate (%)	inhibition	n rate (%)
	100 µg/mL	50 µg/mL	100 µg/mL	50 µg/mL	100 µg/mL	50 µg/mL
D1	71.4 ± 1.4	56.2 ± 0.6	33.2 ± 4.6	32.3 ± 2.3	64.2 ± 0.2	27.5 ± 2.9
D2	56.0 ± 2.9	36.9 ± 2.6	40.9 ± 1.2	38.1 ± 4.7	47.3 ± 1.2	45.2 ± 4.8
D3	87.9 ± 1.7	62.6 ± 2.3	41.8 ± 1.4	39.3 ± 0.2	66.4 ± 4.0	30.5 ± 0.7
D4	40.4 ± 3.8	30.5 ± 3.0	45.1 ± 2.1	40.2 ± 2.4	30.2 ± 4.5	24.9 ± 1.3
D5	90.3 ± 3.6	82.4 ± 2.6	41.3 ± 3.3	29.1 ± 1.3	75.2 ± 3.3	42.2 ± 0.2
D6	70.5 ± 1.4	63.0 ± 0.7	64.8 ± 2.2	55.9 ± 1.1	79.7 ± 1.1	45.0 ± 2.7
D 7	67.7 ± 2.7	62.1 ± 2.1	45.0 ± 4.7	36.3 ± 3.0	47.8 ± 2.8	48.7 ± 4.6
D8	57.8 ± 2.8	42.7 ± 4.1	56.3 ± 4.5	41.5 ± 0.2	74.8 ± 4.5	39.3 ± 4.5
D9	95.9 ± 1.0	90.0 ± 0.2	59.6 ± 1.7	50.5 ± 5.0	53.5 ± 4.2	12.5 ± 2.4
D10	41.1 ± 0.6	35.0 ± 0.2	35.1 ± 4.3	28.0 ± 4.9	22.8 ± 1.4	8.5 ± 1.0
D11	46.5 ± 0.0	23.3 ± 3.4	43.9 ± 3.7	40.6 ± 0.6	50.8 ± 1.8	33.1 ± 4.8
D12	71.8 ± 1.6	57.2 ± 2.0	68.5 ± 4.0	60.6 ± 2.9	89.1 ± 3.2	77.3 ± 0.7
D13	68.0 ± 3.7	61.6 ± 0.1	70.2 ± 3.6	68.7 ± 4.7	45.4 ± 4.8	25.3 ± 1.6
D14	28.9 ± 2.4	26.2 ± 2.5	39.7 ± 2.9	36.9 ± 1.6	34.8 ± 2.8	24.9 ± 1.8
D15	69.3 ± 1.6	73.7 ± 3.1	40.8 ± 1.3	38.1 ± 3.6	36.7 ± 3.6	23.4 ± 0.6
D16	65.1 ± 1.9	52.3 ± 1.1	34.5 ± 2.2	21.9 ± 1.2	20.4 ± 4.7	17.1 ± 1.1
D17	38.2 ± 1.7	21.6 ± 1.9	32.6 ± 0.2	19.1 ± 3.7	35.8 ± 4.1	10.0 ± 0.4
D18	21.1 ± 5.0	19.5 ± 3.8	58.5 ± 0.7	48.6 ± 1.1	8.9 ± 1.9	2.7 ± 1.5
D19	74.1 ± 4.9	63.1 ± 4.3	70.7 ± 2.6	53.2 ± 1.0	59.2 ± 4.8	42.8 ± 4.1
E1	61.4 ± 1.4	44.2 ± 0.6	55.0 ± 4.9	43.8 ± 1.3	54.6 ± 4.9	47.8 ± 3.3
E2	67.4 ± 3.7	59.1 ± 0.3	46.2 ± 3.7	28.4 ± 1.3	50.7 ± 2.1	14.3 ± 0.5
E3	55.9 ± 3.2	47.0 ± 0.4	76.4 ± 2.4	61.1 ± 4.1	71.1 ± 3.9	54.2 ± 4.5
E4	86.9 ± 0.5	55.2 ± 0.9	75.2 ± 3.9	54.4 ± 1.5	20.0 ± 2.5	7.6 ± 2.6
E5	72.9 ± 3.5	58.2 ± 0.2	42.8 ± 2.0	40.1 ± 0.7	56.8 ± 0.6	33.6 ± 2.1
E6	97.8 ± 0.8	87.0 ± 4.8	55.9 ± 2.1	39.3 ± 3.5	58.1 ± 4.3	41.1 ± 4.3
E7	96.9 ± 0.4	95.1 ± 1.3	37.7 ± 2.7	34.4 ± 4.7	74.4 ± 3.3	51.5 ± 3.8
E8	93.5 ± 0.1	66.8 ± 1.3	53.9 ± 3.7	41.3 ± 4.0	53.9 ± 3.0	37.2 ± 0.5
E9	97.4 ± 0.1	91.8 ± 0.1	74.1 ± 0.7	63.3 ± 1.2	69.9 ± 0.1	46.4 ± 2.0
E10	67.9 ± 1.7	63.6 ± 3.2	80.8 ± 0.7	76.4 ± 2.3	54.7 ± 0.6	35.9 ± 1.8
E11	50.3 ± 3.1	30.7 ± 2.7	56.2 ± 2.9	19.2 ± 0.9	53.1 ± 4.2	41.1 ± 1.6
E12	90.1 ± 0.6	88.7 ± 3.7	54.5 ± 4.4	43.1 ± 1.1	47.6 ± 4.6	40.4 ± 1.0
E13	94.3 ± 1.2	81.2 ± 3.1	54.6 ± 1.6	47.4 ± 4.4	81.8 ± 1.9	67.5 ± 3.7
E14	88.3 ± 3.5	69.5 ± 1.3	37.0 ± 2.5	28.8 ± 2.4	28.5 ± 4.3	72.6 ± 2.1
E15	97.9 ± 1.0	76.1 ± 1.8	32.9 ± 1.8	25.9 ± 2.4	27.2 ± 4.7	7.1 ± 3.2
E16	97.2 ± 1.7	79.7 ± 4.6	65.2 ± 3.1	54.0 ± 0.6	72.1 ± 4.7	50.5 ± 3.4
E17	88.7 ± 4.1	84.7 ± 3.1	62.3 ± 2.9	58.2 ± 1.3	70.5 ± 1.7	38.1 ± 1.4
E18	68.5 ± 1.4	50.4 ± 3.4	69.6 ± 0.4	60.6 ± 3.4	65.2 ± 1.1	51.5 ± 4.5
E19	74.9 ± 4.9	63.0 ± 4.3	67.4 ± 4.1	43.5 ± 0.7	65.9 ± 1.3	39.4 ± 3.1
BMT ^b	67.8 ± 2.6	47.3 ± 2.7	59.0 ± 0.7	50.8 ± 2.8	62.8 ± 1.7	44.8 ± 5.0
TDC ^b	65.8 ± 0.5	34.6 ± 1.9	60.8 ± 3.4	42.0 ± 2.2	51.0 ± 1.2	22.0 ± 2.4
^{<i>a</i>} Average of three replicates. ^{<i>b</i>} Commercialized bactericides bismerthiazol (BMT) and thiediazole copper (TDC).						

ferulic acid methyl ester as the starting materials, involving two intermediates **B** and **C**.^{43–45} First, the intermediates **B** and **C** were prepared using a classical literature method with ferulic acid methyl ester used as the starting material.^{43,44} Then, the target compounds **D1–D19** were synthesized in accordance with previous reports.⁴⁵ Finally, due to the conjugate effect of a double bond in α , β -unsaturated amide, the target compounds **D1–D19** were selectively hydrolyzed to prepare the target compounds **E1–E19**.⁴⁴ The details of this synthesis process are shown in the Supporting Information (SI).

In Vitro Antibacterial Activity Test. Using the turbidimetric method in refs 46–48, *in vitro* antibacterial activities of D1–D19 and E1–E19 against *Xoo, Xac,* and *Xoc* were tested. BMT and TDC were used as positive controls. The test method utilized is given in the Supporting Information.

In Vivo Antibacterial Activity Test. The curative and protective activities of compounds E6 and E12 for controlling rice leaf blight were tested *in vivo* by employing a previously reported method with little

modification.⁴⁹ This test method is provided in the Supporting Information (SI).

Scanning Electron Microscopy (SEM) Characterization. The influence of the most active compound E12 on *Xoo* was observed using SEM in accordance with methods previously published,^{48,50} as also shown in the SI.

In Vitro Antifungal Bioassay. The antifungal activities of D1– D19 and E1–E19 against F. oxysporum (F. o.), C. mandshurica (C. m.), C. gloeosporioides (C. g.), G. zeae (G. z.), S. sclerotiorum (S. s.), and R. solani (R. s.) were evaluated using a previously reported method,⁵¹ in which fungicides hymexazol (HM) and carbendazim were put to positive control use. The test particulars can be found in the SI.

Insecticidal Activity Test on Plutella Xylostella (P. xylostella). The insecticidal activities of **D1–D19** and **E1–E19** were obtained using previously published methods.^{52,53} The insecticide chlorpyrifos was employed as a positive control, and distilled water containing 1% DMSO was used as a blank control.

T.1.1. 1	EC '	X7.1	- CT-	C		v_{-a}
I adle 2.	EUro	values	of larget	Compounds	against /	100
	50					

compd.	toxic regression equation	r	EC_{50} (μ g/mL)	compd.	toxic regression equation	r	$EC_{50}(\mu g/mL)$
D1	y = 1.23x + 3.26	0.92	25.6 ± 1.1	E1			
D2				E2	y = 0.41x + 4.10	0.92	77.7 ± 10.0
D3	y = 0.63x + 4.11	0.92	26.8 ± 8.9	E3	y = 0.31x + 4.41	0.95	83.1 ± 8.9
D4				E4	y = 1.42x + 2.60	0.92	49.3 ± 5.2
D5	y = 1.81x + 2.12	0.9	39.1 ± 2.1	E5	y = 1.13x + 2.96	0.99	62.9 ± 9.8
D6	y = 0.71x + 3.77	0.91	53.5 ± 1.0	E6	y = 1.71x + 2.83	0.98	14.6 ± 1.5
D 7	y = 0.42x + 4.20	0.97	78.2 ± 6.1	E7	y = 1.34x + 2.73	0.93	49.5 ± 8.8
D8				E8	y = 2.02x + 2.09	0.97	27.2 ± 0.5
D9	y = 1.57x + 2.58	0.91	34.6 ± 8.1	E9	y = 1.65x + 2.42	0.93	24.0 ± 0.3
D10				E10	y = 2.42x + 1.37	0.97	31.1 ± 1.4
D11				E11	y = 0.46x + 4.19	0.99	55.3 ± 6.5
D12	y = 0.88x + 3.38	0.93	67.8 ± 5.7	E12	y = 1.00x + 3.93	0.98	11.6 ± 3.6
D13	y = 2.07x + 1.47	0.97	49.6 ± 1.1	E13	y = 1.53x + 2.95	0.92	14.8 ± 1.5
D14				E14	y = 1.25x + 2.97	0.94	18.4 ± 5.2
D15	y = 0.81x + 3.94	0.92	19.9 ± 1.9	E15	y = 2.04x + 2.04	0.93	28.1 + 1.1
D16	y = 0.60x + 3.94	0.94	59.6 ± 4.3	E16	y = 1.59x + 2.96	0.91	19.1 ± 5.0
D17				E17	y = 1.21x + 3.26	0.96	27.3 ± 4.3
D18				E18	y = 0.53x + 3.89	0.97	128.2 ± 5.2
D19	y = 1.14x + 3.02	0.95	54.4 ± 6.4	E19			
BMT ^b	y = 0.83x + 3.39	0.91	84.3 ± 9.1	TDC ^b	y = 1.30x + 2.21	0.94	137.8 ± 4.3
Average of t	hree replicates. ^b Commercia	lized bacter	ricides bismerthiazol	(BMT) and	thiediazole copper (TDC).		

pubs.acs.org/JAFC

Article

Table 3. EC₅₀ Values of Target Compounds against Xoc^a

compd.	toxic regression equation	r	EC_{50} ($\mu g/mL$)	compd.	toxic regression equation	r	$EC_{50}(\mu g/mL)$
D1				E1			
D2				E2			
D3				E3	y = 0.75x + 3.92	0.93	29.7 ± 2.3
D4				E4	y = 0.84x + 3.58	0.91	47.7 ± 4.7
D5				E5			
D6	y = 0.21x + 4.74	1.00	17.3 ± 8.2	E6			
D7				E7			
D8				E8			
D9	y = 0.72x + 3.59	1.00	91.5 ± 5.2	E9	y = 0.68x + 4.02	0.96	27.0 ± 3.0
D10				E10	y = 0.82x + 3.96	0.94	18.6 ± 1.9
D11				E11			
D12	y = 0.59x + 3.93	0.95	63.4 ± 9.6	E12			
D13	y = 0.85x + 3.72	0.91	31.9 ± 4.1	E13	y = 0.29x + 4.40	0.92	119.0 ± 2.8
D14				E14			
D15				E15			
D16				E16	y = 0.32x + 4.50	0.95	38.7 ± 4.9
D17				E17	y = 0.35x + 4.46	0.96	32.7 ± 2.3
D18	y = 0.84x + 3.24	0.93	122.8 ± 3.2	E18	y = 0.49x + 4.35	0.92	20.8 ± 6.1
D19	y = 0.59x + 4.14	0.96	29.4 ± 7.4	E19	y = 1.22x + 2.50	0.96	109.9 ± 6.5
BMT ^b	y = 0.47x + 4.10	0.98	80.1 ± 4.3	TDC ^b	y = 0.87x + 3.17	0.97	124.7 ± 5.0
'Average of t	hree replicates. ^b Commercia	lized bacter	ricides bismerthiazol	$\left(BMT\right)$ and	thiediazole copper (TDC).		

RESULTS AND DISCUSSION

Chemistry. As exhibited in the synthetic route (Scheme 1). The intermediate **B** was easily prepared *via* a reaction of starting material **A** with benzyl chloride or benzyl bromine in the presence of KI and K_2CO_3 using *N*,*N*-dimethylformamide as a solvent. Intermediate **B** was hydrolyzed to obtain intermediate **C**, which underwent a reaction with methyl 1-aminocyclohexane-1-carboxylate to obtain the title compounds **D1–D19**.^{43–45} After the hydrolysis of the title compounds **D1–D19**, the title compounds **E1–E19** were prepared.⁴⁴ The compounds **D1–D19** and **E1–E19** were characterized by ¹H, ¹³C, and ¹⁹F NMR, and high-resolution liquid chromatography–mass spectroscopy

(HRMS), and the spectrum information is listed in the Supporting Information.

Analysis of *In Vitro* Activity toward Xoo, Xoc, and Xac. In Vitro Activity Analysis on Xoo. The preliminary activity *in vitro* against bacterium Xoo is listed in Table 1, and the concentration for 50% of maximal effect (EC_{50}) is listed in Table 2. As shown in Table 1, most of the title compounds exhibited good activity at both 100 and 50 μ g/mL. Particularly, the activities of compounds D9, E6, E7, E8, E9, E13, E15, and E16 were close to 100% at 100 μ g/mL, and compounds D3, D5, E4, E12, E4, E12, E14, and E17 recorded more than 88% activities at 100 μ g/mL, which were much higher than that of BMT (67.8%) and TDC (65.8%). While the concentration was set to

D

Table 4. Protection and Curative Activities of Compound E6 and E12 against Rice Bacterial Leaf Blight under Greenhouse Conditions at 200 µg/mL In Vivo

	protection activity (14 days after spraying)			curative activity (14 days after spraying)		
treatment	morbidity (%)	disease index (%)	control efficiency $(\%)^a$	morbidity (%)	disease index (%)	control efficiency $(\%)^a$
E6	100	44.6	49.4	100	51.5	38.6
E12	100	46.7	47.0	100	46.7	44.4
BMT	100	56.9	35.3	100	56.0	33.2
TDC	100	60.0	31.9	100	60.0	28.5
CK ^b	100	88.1		100	83.9	

"Statistical analysis was conducted by ANOVA method under the condition of assumed equal variances (P > 0.05) and not assumed equal variances (P < 0.05). Different uppercase letters indicate the values of protection activity with significant difference among different treatment groups at P < 0.05. "Blank control."



Figure 2. Protective activities of compounds E6 and E12 against rice leaf blight at 200 μ g/mL.

50 μ g/mL, the activities of compounds **D5**, **D9**, **E7**, **E9**, **E12**, and **E13** were also higher than 80%. As shown in Table 2, the EC₅₀ values of the active title compounds ranged from 11.6 to 128.2 μ g/mL. Most of their EC₅₀ values were much lower than these of BMT (84.3 μ g/mL) and TDC (137.8 μ g/mL).

In Vitro Activity Analysis on Xoc. The preliminary activity *in* vitro against bacterium Xoc is listed in Table 1, and the EC₅₀ is listed in Table 3. Compared with the activity toward Xoo, the activity toward Xoc was relatively lower, but there were also 15 compounds that had lower EC₅₀ values ranging from 17.3 to 122.8 μ g/mL, compared to that of TDC (124.7 μ g/mL), and eleven compounds that had lower EC₅₀ values than that of BMT (80.1 μ g/mL).

In Vitro Activity Analysis on Xac. With regards to controlling *Xac* bacterium, most of the title compounds did not exhibit good activity, but compounds **D12** and **E13** showed higher activities, beyond 80% higher, than both BMT (62.8%) and TDC (51.0%) (Table 1).

Structure–Activity Relationship Analysis of Compounds D1–D19 and E1–E19. Based on the results of Tables 1–3, the structure–activity relationship (SAR) was deduced, which concluded the following points: (i) With the same R group, the antibacterial activities of compounds D1– D19 and their hydrolysates E1–E19 are quite different. Generally, most of the hydrolysate E with group –COOH had higher activity *in vitro* than that of compound D. For example, the active compounds E6 (R = 2-F-3-Cl-Ph; EC₅₀ 14.6 μ g/mL),

Ε



Figure 3. Curative activities of compounds E6 and E12 against rice leaf blight at 200 μ g/mL.

E12 (R = 3,4-diF-Ph; EC₅₀ 11.6 μ g/mL), and E13 (R = 3,5-diF-Ph; EC_{50} 14.8) had much lower EC_{50} values against *Xoo* than compounds D6 (R = 2-F-3-Cl-Ph; EC₅₀ 53.5 μ g/mL), D12 (R = 3,4-diF–Ph; EC₅₀ 67.8 μ g/mL), and D13 (R = 3,5-diF-Ph; EC₅₀ 49.6 μ g/mL). The carboxyl strengthening the hydrophobic reaction could be a potential reason for these increases in activity.³⁶ (ii) The R group including a weak electron-donating group -CH₃, strong electron-withdrawing groups -CF₃, -F, and -OCF₃, and moderate electron-withdrawing groups -Cl and -Br could lead to significant differences in antibacterial activity at different positions of the phenyl group. In terms of *Xoo*, the location effect is listed as follows: $D1 (R = 2-CH_3-Ph) >$ $D2 (R = 3-CH_3-Ph); D4 (R = 4-Cl-Ph) > D11 (R = 2-Cl-Ph);$ D10 (R = 3-F-Ph) > D19 (R = 4-F-Ph); D12 (R = 3,4-diF-Ph) >Ph) > E1 (R = 2-CH₃-Ph); E4 (R = 4-Cl-Ph) > E11 (R = 2-Cl-Ph); E19 (R = 4-F-Ph) > E10 (R = 3-F-Ph); and E13 (R = 3,5diF-Ph) > E12 (R = 3,4-diF-Ph) > E17 (R = 2,5-diF-Ph). The location effect also existed when controlling Xoc and Xac. (iii) Halogen atoms substituted in phenyl significantly affected the antibacterial activity. When one or two halogen atoms are substituted in phenyl, the title compounds could have a higher antibacterial activity against both Xoc and Xac to some degree when compared with D15 (R = Ph) and E15 (R = Ph). Moreover **D18**, in which the phenyl is substituted by the Br

atom, or in other compounds where the phenyl is substituted by Cl atom, showed relatively lower activity compared with the compounds where phenyl was substituted by an F atom including D3 and E3 (R = 4-F-5-CF₃-Ph); D6 and E6 (R = 2-F-3-Cl-Ph); D7 and E7 (R = 2-F-6-F-Ph); D8 and E8 (R = 2-Cl-4-F-Ph); D9 and E9 (R = 4-OCF₃-Ph); D10 and E10 (R = 3-F-Ph); D13 and E13 (R = 3,5-diF-Ph); and D19 and E19 (R = 4-F-Ph). The potential factor is that the introduction of fluorine atoms could improve the lipophilicity and bioavailability of these compounds. ^{54,55}

In Vivo Antibacterial Activity Analysis. According to the results in Tables 1–3, it was clear that the title compounds of hydrolysates E6 and E12 showed the lowest EC_{50} values against *Xoo*, reaching 14.6 and 11.6 μ g/mL. Therefore, E6 and E12 were selected to verify their applications within rice crops on rice blight at 200 μ g/mL in a greenhouse. As shown in Table 4 and Figures 2 and 3, the protective activities of both E6 and E12 were 49.4 and 47.0%, which were both higher than BMT (35.3%) and TDC (31.9%). In addition, the curative activity of both E6 and E12 were measured at 38.6 and 44.4%, which were also higher than those of BMT (33.2%) and TDC (28.5%). These results showed that compounds E6 and E12 had an effective efficiency on rice bacterial blight in rice crops and could therefore be considered as antibacterial agent candidates.



Figure 4. SEM images for the influence of E12 on Xoo at (A) 0 μ g/mL, (B) 25.0 μ g/mL, and (C) 50.0 μ g/mL.

Table 5. Antifungal Activities of the Target Compounds D1–D19 and E1–E19 at 50 μ g/mL In Vitro^a

	inhibition rate (%)					
compd.	F. o. ^b	<i>C. m.</i> ^{<i>c</i>}	C. g. ^d	<i>G. z.</i> ^{<i>e</i>}	S. s. ^f	R.s. ^g
D1	7.8 ± 2.6	9.1 ± 1.0	20.9 ± 2.4	10.7 ± 0.4	28.1 ± 1.2	54.0 ± 1.3
D2	0	7.0 ± 0.8	22.1 ± 3.7	11.5 ± 1.0	$28.1 \pm 3.9.$	54.9 ± 2.2
D3	5.7 ± 1.0	8.2 ± 1.3	24.1 ± 3.2	24.2 ± 2.5	23.9 ± 1.6	53.6 ± 2.7
D4	6.3 ± 2.0	10.5 ± 0.9	32.1 ± 1.0	12.5 ± 5.0	16.3 ± 1.2	99.4 ± 1.0
D5	15.0 ± 3.3	9.9 ± 2.5	21.5 ± 3.7	44.2 ± 0.5	36.0 ± 0.9	12.8 ± 3.4
D6	12.1 ± 1.7	17.3 ± 3.5	22.4 ± 1.4	4.3 ± 1.7	23.4 ± 0.9	98.2 ± 0.0
D7	16.4 ± 4.0	14.3 ± 4.0	19.1 ± 0.9	6.8 ± 0.9	29.1 ± 0.0	57.6 ± 2.2
D8	11.8 ± 3.6	11.4 ± 0.9	24.2 ± 0.5	32.5 ± 3.6	17.1 ± 1.2	44.6 ± 0.0
D9	8.9 ± 2.2	7.0 ± 1.8	21.8 ± 0.0	20.6 ± 3.9	20.7 ± 0.5	49.5 ± 0.4
D10	11.2 ± 2.6	8.5 ± 0.5	20.6 ± 2.3	10.0 ± 2.6	19.7 ± 0.0	15.2 ± 4.5
D11	12.9 ± 1.7	14.3 ± 0.5	22.4 ± 3.7	23.9 ± 3.7	29.1 ± 1.6	45.1 ± 0.4
D12	13.5 ± 3.0	13.7 ± 3.3	13.6 ± 1.8	19.2 ± 2.1	23.6 ± 1.6	32.1 ± 2.7
D13	10.9 ± 3.9	14.6 ± 1.0	28.6 ± 3.2	20.1 ± 1.3	13.9 ± 0.6	41.1 ± 3.6
D14	8.6 ± 1.7	13.5 ± 4.8	29.8 ± 2.9	22.2 ± 3.1	25.7 ± 2.5	48.6 ± 1.3
D15	5.7 ± 2.2	8.5 ± 1.0	10.6 ± 0.5	0	20.7 ± 1.6	30.4 ± 0.9
D16	12.5 ± 1.3	9.4 ± 1.3	19.7 ± 5.0	49.6 ± 0.9	35.8 ± 2.8	47.7 ± 3.1
D17	14.4 ± 3.0	12.9 ± 4.0	20.3 ± 1.0	16.2 ± 0.9	24.4 ± 2.8	38.1 ± 4.1
D18	26.4 ± 1.8	15.8 ± 1.8	13.6 ± 4.5	38.7 ± 2.5	34.1 ± 3.0	79.9 ± 2.4
D19	13.5 ± 0.5	14.6 ± 1.8	7.3 ± 1.6	0	33.4 ± 0.4	50.6 ± 2.9
E1	12.0 ± 0.9	8.9 ± 0.3	7.4 ± 0.4	15.9 ± 2.3	71.5 ± 2.8	100.0 ± 1.0
E2	3.4 ± 2.6	5.9 ± 2.5	12.3 ± 0.0	27.7 ± 3.2	26.9 ± 2.1	36.2 ± 3.5
E3	50.1 ± 2.2	13.0 ± 2.8	12.7 ± 0.4	22.7 ± 0.9	31.1 ± 1.8	56.4 ± 4.8
E4	33.7 ± 3.9	32.6 ± 3.7	18.0 ± 3.1	39.9 ± 5.0	47.3 ± 0.5	41.3 ± 4.8
E5	0	0	0	0	0	0
E6	33.0 ± 0.3	23.4 ± 3.3	26.3 ± 0.9	8.6 ± 1.4	34.2 ± 2.3	4.2 ± 2.0
E7	21.4 ± 0.9	5.7 ± 1.5	31.9 ± 1.0	12.1 ± 4.2	24.8 ± 3.0	83.6 ± 2.9
E8	43.4 ± 1.1	8.1 ± 2.4	43.9 ± 0.9	3.6 ± 0.9	24.8 ± 0.0	41.3 ± 1.0
E9	41.4 ± 0.4	30.7 ± 4.1	37.1 ± 4.1	49.7 ± 2.3	67.1 ± 0.4	84.0 ± 1.6
E10	36.4 ± 4.6	5.5 + 1.9	19.3 ± 3.5	12.4 ± 3.0	1.1 ± 1.7	95.6 ± 1.4
E11	42.0 ± 1.5	23.6 ± 4.0	30.1 ± 3.7	50.9 ± 3.6	33.6 ± 3.5	22.3 ± 4.0
E12	24.3 ± 1.2	0	23.7 ± 2.3	0	24.2 ± 3.0	4.8 ± 1.0
E13	22.3 ± 1.8	13.2 ± 2.2	12.0 ± 0.5	26.4 ± 4.8	25.9 ± 2.7	81.2 ± 0.5
E14	22.6 ± 1.7	0	29.5 ± 1.0	0	17.7±1.3	82.2 ± 2.4
E15	16.9 ± 2.0	5.9 ± 1.1	34.7 ± 3.9	0	20.8 ± 1.3	82.2 ± 2.4
E16	36.0 ± 0.9	12.2 ± 0.3	38.3 ± 3.7	50.9 ± 3.6	42.1 ± 4.9	56.9 ± 4.0
E17	31.7 ± 3.8	38.2 ± 2.6	32.5 ± 1.8	0.6 ± 4.2	31.6 ± 1.7	42.3 ± 1.9
E18	27.4 ± 4.4	29.8 ± 1.6	39.2 ± 3.1	29.7 ± 4.2	38.5 ± 2.6	28.1 ± 3.1
E19	18.0 ± 3.7	10.0 ± 1.7	21.3 ± 3.3	0	30.5 ± 2.0	57.7 ± 0.0
HM ^h	37.2 ± 3.7	43.0 ± 3.1	61.2 ± 2.3	58.5 ± 4.3	48.6 ± 1.9	65.7 ± 1.4
carbendazim	98.3 ± 0.1	100.0 ± 0.0	99.4 + 1.0	98.3 ± 0.0	97.0 + 2.1	100.0 + 0.0

= R. solani. ^hCommercialized agrofungicide hymexazol (HM).

Scanning Electron Microscopy (SEM) Characterization Analysis. With the help of SEM, morphological observation of bacterium *Xoo* was carried out and morphological differences following treatment with the most active compound **E12** were

comp.	pathogens	regression equation	correlation coefficient (r)	$EC_{50}(\mu g/mL)$
E1	S. s.	y = 0.41x + 4.27	0.94	60.6 ± 4.6
E9	S. s.	y = 1.12x + 3.16	0.94	43.8 ± 4.5
HM^b	S. s.	y = 0.99x + 3.03	0.94	96.3 ± 3.6
carbendazim	S. s.	y = 1.31x + 4.86	0.92	1.3 ± 0.7
D4	<i>R. s.</i>	y = 1.89x + 3.58	0.95	5.6 ± 1.1
D6	<i>R. s.</i>	y = 2.27x + 2.57	0.90	11.7 ± 0.7
D18	<i>R. s.</i>	y = 0.66x + 4.33	0.98	10.1 ± 1.3
E1	<i>R. s.</i>	y = 0.41x + 5.93	0.94	0.005 ± 0.004
E7	<i>R. s.</i>	y = 051x + 4.78	0.96	2.6 ± 1.0
E9	<i>R. s.</i>	y = 047x + 4.91	0.99	1.6 ± 1.0
E10	<i>R. s.</i>	y = 0.64x + 5.28	0.91	0.370 ± 0.117
E13	<i>R. s.</i>	y = 0.29x + 5.23	0.95	0.159 ± 0.002
E14	<i>R. s.</i>	y = 0.53x + 4.74	0.91	3.1 ± 0.3
E15	<i>R. s.</i>	y = 0.44x + 4.85	0.96	2.1 ± 0.4
HM ^b	<i>R. s.</i>	y = 0.76x + 3.57	0.92	74.8 ± 0.7
carbendazim	<i>R. s.</i>	y = 1.21x + 5.09	0.90	0.8 ± 0.5
Array of three nonlinet	bThe emissibultured for	ariaida humananal (UM) una u	and to commune the entitiencel estimit	iss of the title some over

Table 6. EC₅₀ values of Active Compounds against Fungi S. s., and R. s. In Vitro^a

"Average of three replicates. "The agricultural fungicide hymexazol (HM) was used to compare the antifungal activities of the title compounds.

analyzed in more depth. As shown in Figure 4 A, the bacterium *Xoo* grown without the addition of the compound solution treatment had slender cells with a hard surface, thus classified as a good appearance. After the treatment of **E12**, the cell membranes of *Xoo* collapsed to a varying degree; as the **E12** concentrations increased, cell membrane damage severity also increased (Figure 4B,C). From the SEM characterization of *Xoo*, it was clear that **E12** resulted in cell membrane deformation or rupture, which could be the potential mechanism to inhibit bacterial growth.

In Vitro Antifungal Activity Analysis. The preliminary antifungal activities of D1-D19 and E1-E19 against six fungi, including F. o., C. m., C. g., G. z., S. s., and R. s. are concluded in Table 5, and the EC_{50} values of the active compounds are shown in Table 6. The data revealed that the compounds displayed good to excellent antifungal activity against F. o., S. s., and R. s. at 50 μ g/mL, particularly E3 and E8, which had good activities at 50.1 and 43.4% against F. o., E9, which had good activities at 41.4, 67.1, and 84.0% against F. o., S. s., and R. s., respectively, E11, which had good activity at 42.0% against F. o., E1, which had excellent activity at 71.5% and 100.0% against S. s. and R. s., respectively, D4, which showed significantly high activity at 99.4% against S. s., D6, which showed significantly high activity at 98.2% against S. s., D18, which showed excellent activity at 79.9% against S. s., E7, which showed excellent activity at 83.6% against S. s., E10, which showed significantly high activity at 95.6% against S. s., E13, which showed excellent activity at 81.2% against S. s., E14, which showed excellent activity 82.2% against S. s., and E15, which showed excellent activity at 82.2% against S. s. All of the antifungal activity levels above were higher than those of HM (37.2, 48.6, and 65.7% against F. o., S. s., and R. s., respectively), and antifungal activity against R. s. of compounds D4, D6, E1, and E10 were also similar to that of carbendazim 100%. As shown in Table 6, the active compounds E1 and E9 provided impressive actions toward S. s., with the EC_{50} values of 60.4 and 43.8 μ g/mL, respectively, which were evidently higher than that of HM (96.3 μ g/mL). Moreover, the active compounds D4, D6, D18, E1, E7, E9, E10, E13, E14, and E15 had the EC₅₀ values of 5.6, 11.7, 10.1, 0.005, 2.6, 1.6, 0.37, 0.159, 3.1, and 2.1 μ g/mL, respectively, much better than the HM levels (74.8 μ g/mL). The EC₅₀ values of compounds E1, E10, and E13 were also lower than that of carbendazim (0.8 μ g/

mL). Among them, the most active compound E1 (R = 2-CH₃– Ph) had the lowest EC_{50} value, which reached 0.005 μ g/mL and effectively controlled the growth of the fungus *R*. *s*. at a range of concentrations (Figure S1). From Tables 5 and 6, it can be observed that the synthesized compounds had the highest activity against *R*. *s*. but no activity against *C*. *m.*, *C*. *g.*, or *G*. *z*. It should be noted that most of the hydrolysates E obtained *via* hydrolysis of **D** also exhibited a higher activity than the title compound **D** itself. These results indicated that synthesized novel ferulic amide Ac6c derivatives could also be considered as antifungal agents for further structural modification.

Insecticidal Activity Analysis. Table 7 lists the results of the insecticidal activities for D1–D19 and E1–E19 against *P*.

Table 7. Insecticidal Activities of the Title Compounds against P. xylostella

	P. xylostella		P. xylostella
compd.	500 μ g/mL mortality rate (%) ^{<i>a</i>}	compd.	500 μ g/mL mortality rate (%) ^{<i>a</i>}
D1	50.3 ± 1.0	E1	33.3 ± 1.5
D2	40.2 ± 1.0	E2	37.1 ± 3.0
D3	40.6 ± 2.5	E3	47.4 ± 3.8
D4	55.1 ± 0.5	E4	57.6 ± 1.7
D5	53.9 ± 1.6	E5	80.6 ± 0.6
D6	37.3 ± 1.2	E6	23.8 ± 1.2
D 7	45.4 ± 0.5	E7	63.0 ± 0.6
D8	6.7 ± 1.0	E8	33.4 ± 1.0
D9	67.9 ± 0.5	E9	20.7 ± 2.1
D10	57.8 ± 0.5	E10	73.4 ± 1.5
D11	37.0 ± 0.5	E11	50.7 ± 4.2
D12	60.3 ± 0.5	E12	20.9 ± 0.6
D13	73.7 ± 2.0	E13	47.3 ± 1.0
D14	57.3 ± 2.0	E14	5.4 ± 3.2
D15	63.1 ± 0.5	E15	33.7 ± 1.7
D16	67.5 ± 1.0	E16	50.9 ± 2.0
D17	40.9 ± 1.0	E17	50.2 ± 2.0
D18	47.4 ± 0.5	E18	30.8 ± 1.5
D19	50.6 ± 2.3	E19	30.1 ± 4.3
blank control	0	chlorpyrifos	100.0 ± 0.0

^aaverage of three replicates.

xylostella at 500 μ g/mL. Some compounds showed moderate insecticidal activity, such as compounds **D13** (R = 3.5-diF–Ph), **E5** (R = CH₂CH₂CH₂Cl), and **E10** (R = 3-F–Ph) showed activities of 73.7, 80.6, and 73.4%, respectively. Obviously, the synthesized compounds did not exhibit good insecticidal activity toward *P. xylostella*, but the structural modification of these structures for exploring the insecticidal molecules is ongoing in our laboratory.

In conclusion, novel ferulic amide Ac6c derivatives were synthesized in the present work, and bioassays targeting three kinds of bacteria (Xoo, Xoc, and Xac), six kinds of fungi (F. oxysporum, C. mandshurica, C. gloeosporioides, G. zeae, S. sclerotiorum, and R. solani), and the pest P. xylostella were carried out. Some more active synthesized compounds were compared against commercial pesticides, and screening indicated that they should be considered as agrochemical candidates, such as E6 and E12, which showed significantly higher activity against Xoo and also performed well in the pot experiment and SEM of in vivo studies. E1 whose EC₅₀ value reached 0.005 toward the fungus R. solani was an example. Through the structure-activity relationship, it was shown that in most cases, the hydrolysis of the title compound D resulted in the more active title compound E, which could be an inspiration for the discovery of agrochemical agents.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jafc.1c03892.

Mycelium growth and extension of *R. solani* after treatment with different concentrations of E1 on agar medium (Figure S1). All of the general procedures of the experiments, the characterizations, physical, analytical data, and NMR copies of the synthesized compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

Jian Wu – State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China;
orcid.org/0000-0002-9173-6608; Phone: +86-851-88292090; Email: jwu6@gzu.edu.cn, wujian2691@ 126.com

Authors

Renfeng Zhang – State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China

- Shengxin Guo State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China
- Peng Deng State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China

Ya Wang – State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang 550025, China Ali Dai – State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of

Education, Guizhou University, Guiyang 550025, China

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jafc.1c03892

Author Contributions

[†]R.Z. and S.G. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We would like to express our thanks for the financial support from NSFC (Natural Science Foundation of China) (Nos. 21762012, 32072445, and 21562012), the Program of Introducing Talents to Chinese Universities (111 Program, D20023), and the S & T Planning Project of Guizhou Province (Nos. [2017] 1402 and [2017] 5788).

REFERENCES

(1) Guo, S. X.; He, F.; Song, B. A.; Wu, J. Future Direction of Agrochemical Development for Plant Disease in China. *Food Energy Secur.* 2021, No. e293.

(2) Carvalho, F. P. Pesticides, environment, and food safety. *Food Energy Secur.* **2017**, *6*, 48–60.

(3) Bauske, M. J.; Mallik, I.; Yellareddygari, S. K. R.; Gudmestad, N. C. Spatial and temporal distribution of mutations conferring QoI and SDHI Resistance in Alternaria solani Across the United States. *Plant Dis.* **2018**, *102*, 349–358.

(4) Savary, S.; Willocquet, L.; Pethybridge, S. J.; Esker, P.; McRoberts, N.; Nelson, A. The global burden of pathogens and pests on major food crops. *Nat. Ecol. Evol.* **2019**, *3*, 430–4439.

(5) Samaras, A.; Hadjipetrou, C.; Karaoglanidis, G. Bacillus amyloliquefaciens strain QST713 may contribute to the management of SDHI resistance in Botrytis cinerea. *Pest Manage. Sci.* 2021, 77, 1316–1327.

(6) Zhu, P. L.; Zhao, S. A.; Tang, J. L.; Feng, J. X. The rsmA-like gene $rsmA_{Xoo}$ of *Xanthomonas oryzae* pv. *Oryzae* regulates bacterial virulence and production of diffusible signal factor. *Mol. Plant Pathol.* **2011**, *12*, 227–237.

(7) Zou, L. F.; Wang, X. P.; Xiang, X.; Zhang, B.; Li, Y. R.; Xiao, Y. L.; Wang, J. S.; Walmsley, A. R.; Chen, G. Y. Elucidation of the *hrp* Clusters of *Xanthomonas oryzae* pv. *oryzicola* That Control the Hypersensitive Response in Nonhost Tobacco and Pathogenicity in Susceptible Host Rice. *Appl Environ. Microbiol.* **2006**, *72*, 6212–6224.

(8) Xiang, J.; Liu, D. Y.; Chen, J. X.; Hu, D. Y.; Song, B. A. Design and synthesis of novel 1,3,4-oxadiazole sulfone compounds containing 3,4-dichloroisothiazolylamide moiety and evaluation of rice bacterial activity. *Pestic. Biochem. Physiol.* **2020**, *164*, 26–32.

(9) Bae, N.; Park, H. J.; Park, H.; Kim, M.; Han, S. W. Deciphering the functions of the outer membrane porin OprBXo involved in virulence, motility, exopolysaccharide production, biofilm formation, and stress tolerance in *Xanthomonas oryzae* pv. *Oryzae*. *Mol. Plant Pathol.* **2018**, 19, 2527–2542.

(10) Zhang, Y. C.; Zou, Y. N.; Liu, L. P.; Wu, Q. S. Common mycorrhizal networks activate salicylic acid defense responses of trifoliate orange (*Poncirus trifoliata*). *J. Integr. Plant Biol.* **2019**, *61*, 1099–1111.

(11) Moreira, L. M.; Soares, M. R.; Facincani, A. P.; Ferreira, C. B.; Ferreira, R. M.; Ferro, M. I. T.; Gozzo, F. C.; Felestrino, E. B.; Assis, R. A. B.; Garcia, C. C. M.; Setubal, J. C.; Ferro, J. A.; Oliveira, J. C. F. Proteomics-based identification of differentially abundant proteins reveals adaptation mechanisms of *Xanthomonas citri* subsp. *citri* during *Citrus sinensis* infection. *BMC Microbiol.* **2017**, *17*, No. 155.

(12) Bauske, M. J.; Gudmestad, N. C. Parasitic Fitness of Fungicide-Resistant and-Sensitive Isolates of *Alternaria solani*. *Plant Dis.* **2018**, *102*, 666–673.

(13) Samaras, A.; Ntasiou, P.; Myresiotis, C.; Karaoglanidis, G. Multidrug resistance of *Penicillium expansum* to fungicides: whole transcriptome analysis of MDR strains reveals overexpression of efflux transporter genes. *Int. J. Food Microbiol.* **2020**, *335*, No. 108896.

(14) Fan, Z. J.; Shi, J.; Luo, N.; Bao, X. P. Synthesis, crystal structure and antimicrobial activity of 2-((2-(4-(1*H*-1,2,4-triazol-1-yl)phenyl)-quinazolin-4-yl)oxy)-*N*-phenylacetamide derivatives against phytopathogens. *Mol. Diversity* **2019**, *23*, 615–624.

(15) Wu, M.; Wang, Z. W.; Meng, C. S.; Wang, K. L.; Hu, Y. N.; Wang, L. Z.; Wang, Q. M. Discovery and SARs of trans-3-aryl acrylic acids and their analogs as novel anti-tobacco mosaic virus (TMV) agents. *PLoS One* **2013**, *8*, No. e56475.

(16) Tang, X.; Zhang, C.; Chen, M.; Xu, Y. N.; Liu, T. T.; Xue, W. Synthesis and Antiviral Activity of Novel Myricetin Derivatives Containing a Ferulic Acid Amide Scaffolds. *New J. Chem.* **2020**, *44*, 2374–2379.

(17) Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine—ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2905–2909.

(18) Kwon, Y. S.; Kobayashi, A.; Kajiyama, S. I.; Kawazu, K.; Kanzaki, H.; Kim, C. M. Antimicrobial constituents of Angelica dahurica roots. *Phytochemistry* **1997**, *44*, 887–889.

(19) Li, W. X.; Li, N. G.; Tang, Y. P.; Li, B. Q.; Liu, L.; Zhang, X.; Fu, H. A.; Duan, J. A. Biological activity evaluation and structure–activity relationships analysis of ferulic acid and caffeic acid derivatives for anticancer. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6085–6088.

(20) Li, J. M.; Zhao, Y. H.; Ma, F. S.; Wang, Z. Y.; He, Y.; Zhang, D. S.; Ren, H. B. Synthesis of Ligustrazine-Aromatic Acid Derivatives and Their Inhibitory Effect on Platelet Aggregation. *Chin. J. Org. Chem.* **2008**, *28*, 1578–1583.

(21) Sergent, T.; Piront, N.; Meurice, J.; Toussaint, O.; Schneider, Y. J. Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. *Chem.-Biol. Interact.* **2010**, *188*, 659–667.

(22) Huang, G. Y.; Cui, C.; Wang, Z. P.; Li, Y. Q.; Xiong, L. X.; Wang, L. Z.; Yu, S. J.; Li, Z. M.; Zhao, W. G. Synthesis and characteristics of (Hydrogenated) ferulic acid derivatives as potential antiviral agents with insecticidal activity. *Chem. Cent. J.* **2013**, *7*, No. 33.

(23) Gan, X. H.; Hu, D. Y.; Wang, Y. J.; Yu, L.; Song, B. A. Novel transFerulic Acid Derivatives Containing a Chalcone Moiety as Potential Activator for Plant Resistance Induction. *J. Agric. Food Chem.* **2017**, *65*, 4367–4377.

(24) Lan, X. M.; Xie, D. D.; Yin, L. M.; Wang, Z. Z.; Chen, J.; Zhang, A. W.; Song, B. A.; Hu, D. Y. Novel α , β -unsaturated amide derivatives bearing α -amino phosphonate moiety as potential antiviral agents. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 4270–4273.

(25) Wang, Z. Z.; Xie, D. D.; Gan, X. H.; Zeng, S.; Zhang, A. W.; Yin, L. M.; Song, B. A.; Jin, L. H.; Hu, D. Y. Synthesis, antiviral activity, and molecular docking study of trans-ferulic acid derivatives containing acylhydrazone moiety. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 4096–4100.

(26) Ji, X. F.; Wang, Z. W.; Dong, J.; Liu, Y. X.; Lu, A. D.; Wang, Q. M. Discovery of Topsentin Alkaloids and Their Derivatives as Novel Antiviral and Anti-phytopathogenic Fungus Agents. *J. Agric. Food Chem.* **2016**, *64*, 9143–9151.

(27) Vaidya, A. S.; Helander, J. D. M.; Peterson, F. C.; Elzinga, D.; Dejonghe, W.; et al. Dynamic control of plant water use using designed ABA receptor agonists. *Science* **2019**, *366*, No. eaaw8848.

(28) Dejonghe, W.; Okamoto, M.; Cutler, S. R. Small molecule probes of ABA biosynthesis and signaling. *Plant Cell Physiol.* **2018**, *59*, 1490–1499.

(29) Abercrombie, J. J.; Leung, K. P.; Chai, H.; Hicks, R. P. Spectral and biological evaluation of a synthetic antimicrobial peptide derived

from 1-aminocyclohexane carboxylic acid. *Bioorg. Med. Chem.* **2015**, *23*, 1341–1347.

pubs.acs.org/JAFC

(30) Todorov, P.; Peneva, P.; Tchekalarova, J.; Georgieva, S. Potential anticonvulsant activity of novel VV-hemorphin-7 analogues containing unnatural amino acids: synthesis and characterization. *Amino Acids* **2020**, *52*, 567–585.

(31) Naydenova, E.; Wesselinova, D.; Staykova, S.; Danalev, D.; Dzimbova, T. Synthesis, in vitro biological activity and docking of new analogs of BIM-23052 containing unnatural amino acids. *Amino Acids* **2019**, *51*, 1247–1257.

(32) Staykova, S. T.; Wesselinova, D. W.; Vezenkov, L. T.; Naydenova, E. D. Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids. *Amino Acids* **2015**, *47*, 1007–1013.

(33) Abshire, C. J. Toxicity of several cyclohexyl amino acids towards *Escherichia coli* 9723. *Can. J. Biochem* **196**7, *45*, 1004–1008.

(34) Hayashi, M.; Manabe, H.; Sasama, Y.; Wakisaka, S. Preparation of S-phenylisothiazole-1,1-dione compounds as insecticides and acaricides. JP Patent JP113227311999).[Chem. Abstr. 1999, 131, 351323].

(35) Himmler, T.; Fischer, R.; Gallenkamp, B.; Knops, H. J.; Mulder, L. Method for the preparation of 4-alkoxy-1-aminocyclohexanecarboxylates. WO Patent WO20020025322001).[Chem. Abstr. 2001, 136, 85628].

(36) Hertz, C. G. Serum and urinary concentrations of cyclacillin in humans. *Antimicrob. Agents Chemother.* **1973**, *4*, 361–365.

(37) Ackermannd, P.; Fischer, H.; Vogel, R.; Drauz, K.; Hasseberg, H. A.; Hasselbach, H. J.; Knaup, G.; Krimmer, H. P.; Schaefer, M. Preparation of 1-aminocyclohexanecarboxylic acid derivatives as agrochemical fungicides. EP Patent EP4394261991).[Chem. Abstr. 1991, 115, 279487].

(38) Mykhailiuk, P. K.; Starova, V.; Iurchenko, V.; Shishkina, S. V.; Shishkin, O. V.; Khilchevskyi, O.; Zaporozhets, O. 1-Amino-4,4difluorocyclohexanecarboxylic acid as a promising building block for drug discovery: design, synthesis and characterization. *Tetrahedron* **2013**, *69*, 4066–4075.

(39) Mann, A. Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry. In *The Practice of Medicinal Chemistry*; 3rd ed.; Wermuth, C. G., Ed.; Academic/Elsevier: Amsterdam, The Netherlands, 2008; pp 363–379.

(40) Martin, S. F. Preorganization in biological systems: Are conformational constraints worth the energy? *Pure Appl. Chem.* 2007, 79, 193–200.

(41) Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. *J. Pharmacol. Toxicol. Methods* **2000**, *44*, 235–249.

(42) Xie, R. L. Study on Synthesis and Activity of Novel Pesticide compounds by the Method of Cluster effect and substructure combination. Ph.D. Thesis, Zhejiang University: Hanghzou, China, 2013. http://cdmd.cnki.com.cn/Article/CDMD-82101-1013357106. htm (accessed 2019 -09-10, in Chinese).

(43) Luo, D. X.; Guo, S. X.; He, F.; Chen, S. H.; Dai, A. L.; Zhang, R. F.; Wu, J. Design, Synthesis, and Bioactivity of α -Ketoamide Derivatives Bearing a Vanillin Skeleton for Crop Diseases. *J. Agric. Food Chem.* **2020**, *68*, 7226–7234.

(44) Wang, Z. W.; Wang, L.; Ma, S.; Liu, Y. X.; Wang, L. Z.; Wang, Q. M. Design, Synthesis, Antiviral Activity, and SARs of 14-Amino-phenanthroindolizidines. *J. Agric. Food Chem.* **2012**, *60*, 5825–5831.

(45) Caulfield, T. J.; Clemens, J.; Francis, R. S.; Freed, B. S.; John, S.; Le, T. B.; Pedgrift, B.; Ramos, A. D.; Rosse, G.; Smrcina, M.; Thorpe, D. S.; Wire, W.; Zhao, J. H. Preparation of substituted fused arylcarboxylic acids and their amides, particularly (acylamino) indanecarboxylic acids, as inhibitors of the CXCR5 receptor for use in the treatment of disorders such as inflammation, rheumatoid arthritis, and asthma. WO Patent WO20081512112007).[Chem. Abstr. 2007, 150, 35056].

(46) Yang, L.; Bao, X. P. Synthesis of novel 1,2,4-triazole derivatives containing the quinazolinylpiperidinyl moiety and *N*-(substituted phenyl)acetamide group as efficient bactericides against the phytopathogenic bacterium *Xanthomonas oryzae* pv. - *oryzae*. *RSC Adv.* **2017**, *7*, 34005–34011.

(47) Xu, W. M.; Han, F. F.; He, M.; Hu, D. Y.; He, J.; Yang, S.; Song, B. A. Inhibition of Tobacco Bacterial Wilt with Sulfone Derivatives Containing an 1,3,4-Oxadiazole Moiety. *J. Agric. Food Chem.* **2012**, *60*, 1036–1041.

(48) Shi, J.; Ding, M. H.; Luo, N.; Luo, S. R.; Li, P. J.; Li, J. H.; Bao, X. P. Design, Synthesis, Crystal Structure, and Antimicrobial Evaluation of 6-Fluoroquinazolinylpiperidinyl-Containing 1,2,4-Triazole Mannich Base Derivatives against Phytopathogenic Bacteria and Fungi. *J. Agric. Food Chem.* **2020**, *68*, 9613–9623.

(49) Fan, Z. J.; Shi, J.; Luo, N.; Ding, M. H.; Bao, X. P. Synthesis, crystal structure, and agricultural antimicrobial evaluation of novel quinazoline thioether derivatives incorporating the 1, 2, 4-triazolo [4, 3-a] pyridine moiety. *J. Agric. Food Chem.* **2019**, *67*, 11598–11606.

(50) Tao, Q. Q.; Liu, L. W.; Wang, P. Y.; Long, Q. S.; Zhao, Y. L.; Jin, L. H.; Xu, W. M.; Chen, Y.; Li, Z.; Yang, S. Synthesis and in vitro and in vivo biological activity evaluation and quantitative proteome profiling of oxadiazoles bearingflexible heterocyclic patterns. *J. Agric. Food Chem.* **2019**, *67*, 7626–7639.

(51) Zhou, L.; Wang, P. Y.; Zhou, J.; Shao, W. B.; Fang, H. S.; Wu, Z. B.; Yang, S. Antimicrobial activities of pyridinium-tailored pyrazoles bearing 1,3,4-oxadiazole scaffolds. *J. Saudi Chem. Soc.* **2017**, *21*, 852–860.

(52) Luo, D. X.; Guo, S. X.; He, F.; Wang, H. Y.; Xu, F. Z.; Dai, A. L.; Zhang, R. F.; Wu, J. Novel Anthranilic Derivatives Bearing the Chiral Thioether and Trifluoromethylpyridine: Synthesis and Bioactivity. *Bioorg. Med. Chem. Lett.* **2020**, *30*, No. 126902.

(53) Xu, F. Z.; Wang, Y. Y.; Luo, D. X.; Yu, G.; Wu, Y. K.; Dai, A. L.; Zhao, Y. H.; Wu, J. Novel Trifluoromethyl Pyridine Derivatives Bearing a 1,3,4-Oxadiazole Moiety as Potential Insecticide. *ChemistrySelect* **2018**, 3, 2795–2799.

(54) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001-2011). *Chem. Rev.* **2014**, *114*, 2432– 2506.

(55) Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A. Applications of fluorine in medicinal chemistry. *J. Med. Chem.* **2015**, 58, 8315–8359.